Studies show that more than half of patients who discontinue GLP-1 treatment regain at least some of the lost weight within a year, as hunger, cravings, and food noise return and drive them back to unhealthy habits
It could be due to the role of GLP-1s in lowering inflammation or decreasing plaque buildup within the arteries, he adds
Lifestyle Strategies (Non-Negotiable) Resistance Training 3-4x per week: This is the ONLY intervention proven to prevent bone loss during GLP-1 therapy
The research was part of a study focused on creating a defense against skin cancer by finding a way to stimulate natural melanin production (melanogenesis) in the skin without exposing it to harmful ultraviolet (UV) radiation from sunlight
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
Large medical references do not classify escitalopram as an addictive drug